U.S. Drug Manufacturers Stock News
Categories
- All
- Editor's Picks
- Stock Market News
- Q&A with Gurus
- Gurus' Stock Picks
- Insider Transaction
- Earning Reports
- CEO Shareholder Letters
- Press Release
- Earnings Call Transcripts
- Instant Alerts
- Podcast
Industries
- Aerospace & Defense
- Agriculture
- Asset Management
- Banks
- Beverages - Alcoholic
- Beverages - Non-Alcoholic
- Biotechnology
- Building Materials
- Business Services
- Capital Markets
- Chemicals
- Conglomerates
- Construction
- Consumer Packaged Goods
- Credit Services
- Diversified Financial Services
- Drug Manufacturers
- Education
- Farm & Heavy Construction Machinery
- Forest Products
- Furnishings, Fixtures & Appliances
- Hardware
- Healthcare Plans
- Healthcare Providers & Services
- Homebuilding & Construction
- Industrial Distribution
- Industrial Products
- Insurance
- Interactive Media
- Manufacturing - Apparel & Accessories
- Media - Diversified
- Medical Devices & Instruments
- Medical Diagnostics & Research
- Medical Distribution
- Metals & Mining
- Oil & Gas
- Other Energy Sources
- Packaging & Containers
- Personal Services
- Real Estate
- REITs
- Restaurants
- Retail - Cyclical
- Retail - Defensive
- Semiconductors
- Software
- Steel
- Telecommunication Services
- Tobacco Products
- Transportation
- Travel & Leisure
- Utilities - Independent Power Producers
- Utilities - Regulated
- Vehicles & Parts
- Waste Management
Nauman khan Drug Manufacturers Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings
Eli Lilly Projects Lower Than Expected 2024 Revenue, Shares Tumble Oct 31, 2024
Drug Manufacturers
Bristol-Myers Squibb Co (BMY) Q3 2024 Earnings: Revenue Surpasses Estimates at $11.9 Billion, GAAP EPS at $0.60
Key Financial Highlights and Strategic Developments Oct 31, 2024
Drug Manufacturers
Amgen Inc (AMGN) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Pipeline Advancements
Amgen Inc (AMGN) reports a 23% revenue increase, driven by strong product sales and promising developments in its innovative pipeline. Oct 31, 2024
Drug Manufacturers
Eli Lilly and Co (LLY) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic Investments Propel Performance
Driven by new product successes and strategic investments, Eli Lilly and Co (LLY) reports a 42% revenue increase, setting a strong foundation for future growth. Oct 31, 2024
Drug Manufacturers
AbbVie Inc (ABBV) Q3 2024 Earnings Call Highlights: Strong Growth in Ex-Humira Platform and Dividend Increase
AbbVie Inc (ABBV) reports robust sales growth driven by Skyrizi and Rinvoq, raises full-year guidance, and announces a 5.8% dividend increase. Oct 31, 2024
Drug Manufacturers
Intra-Cellular Therapies Inc (ITCI) Q3 2024 Earnings Call Highlights: Robust Sales Growth and Strategic Pipeline Developments
Intra-Cellular Therapies Inc (ITCI) reports a 39% increase in net product sales and raises full-year guidance, driven by CAPLYTA's market potential and a strong financial position. Oct 31, 2024
Drug Manufacturers
Biogen Inc (BIIB) Q3 2024 Earnings Call Highlights: Navigating Revenue Declines and Strategic Growth Opportunities
Despite challenges in key segments, Biogen Inc (BIIB) raises EPS guidance and showcases promising growth in its rare disease franchise and pipeline potential. Oct 31, 2024
Drug Manufacturers
Neurocrine Biosciences Inc (NBIX) Q3 2024 Earnings Call Highlights: Strong Sales and Strategic Growth Initiatives
Neurocrine Biosciences Inc (NBIX) reports robust Q3 sales and outlines strategic plans for future growth amidst market challenges. Oct 31, 2024
Drug Manufacturers
Decoding Neurocrine Biosciences Inc (NBIX): A Strategic SWOT Insight
Insightful Analysis of Neurocrine Biosciences Inc's Financial Health and Strategic Position Oct 31, 2024
Drug Manufacturers
Eli Lilly and Co (LLY): A Strategic SWOT Insight into Pharma's Future
Decoding Eli Lilly's Latest Financials and Strategic Position Oct 31, 2024
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers